EP2970894A4 - Stem cell culture media and methods of enhancing cell survival - Google Patents

Stem cell culture media and methods of enhancing cell survival Download PDF

Info

Publication number
EP2970894A4
EP2970894A4 EP14767366.9A EP14767366A EP2970894A4 EP 2970894 A4 EP2970894 A4 EP 2970894A4 EP 14767366 A EP14767366 A EP 14767366A EP 2970894 A4 EP2970894 A4 EP 2970894A4
Authority
EP
European Patent Office
Prior art keywords
methods
culture media
enhancing
cell culture
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14767366.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2970894A1 (en
Inventor
Betsy Denise REZNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of EP2970894A1 publication Critical patent/EP2970894A1/en
Publication of EP2970894A4 publication Critical patent/EP2970894A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
EP14767366.9A 2013-03-15 2014-03-14 Stem cell culture media and methods of enhancing cell survival Withdrawn EP2970894A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792818P 2013-03-15 2013-03-15
PCT/US2014/027521 WO2014152603A1 (en) 2013-03-15 2014-03-14 Stem cell culture media and methods of enhancing cell survival

Publications (2)

Publication Number Publication Date
EP2970894A1 EP2970894A1 (en) 2016-01-20
EP2970894A4 true EP2970894A4 (en) 2017-01-04

Family

ID=51581254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14767366.9A Withdrawn EP2970894A4 (en) 2013-03-15 2014-03-14 Stem cell culture media and methods of enhancing cell survival

Country Status (7)

Country Link
US (2) US9943545B2 (OSRAM)
EP (1) EP2970894A4 (OSRAM)
JP (2) JP2016513472A (OSRAM)
CN (1) CN105358679A (OSRAM)
AU (1) AU2014239290B2 (OSRAM)
CA (1) CA2906641C (OSRAM)
WO (1) WO2014152603A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114796C2 (uk) * 2011-09-30 2017-08-10 Блубьод Байо, Інк. Спосіб підвищення ефективності трансдукції
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
SG10202101358XA (en) 2015-01-26 2021-03-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
WO2016120891A1 (en) * 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
ES2953925T3 (es) 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
CN105713880A (zh) * 2016-04-20 2016-06-29 广东艾时代生物科技有限责任公司 一种造血干细胞体外扩增培养的无血清培养基及其应用
CN105749252B (zh) * 2016-04-29 2025-11-14 南方医科大学 Il-9作为治疗血小板缺少症的药物的应用
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN106434549A (zh) * 2016-12-20 2017-02-22 江西宜信堂医疗科技有限公司 一种无血清干细胞培养基及其制备方法
KR102018609B1 (ko) * 2017-04-26 2019-09-06 이장호 중간엽 줄기세포 배양액을 포함하는 세포 또는 조직의 동결보존용 조성물
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
KR102725720B1 (ko) * 2017-12-29 2024-11-06 셀 큐어 뉴로사이언시스 리미티드 망막 색소 상피 세포 조성물
JP7036670B2 (ja) * 2018-05-31 2022-03-15 アークレイ株式会社 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管
CN110894490A (zh) * 2018-09-13 2020-03-20 李陶 一种脐带造血干细胞体外扩增培养体系和脐带造血干细胞体外扩增方法
JP2022512810A (ja) * 2018-10-24 2022-02-07 ヒービセル コーポレイション 造血系統細胞を製造するための方法およびシステム
US20220220561A1 (en) * 2019-03-18 2022-07-14 Advanced ReGen Medical Technologies, LLC Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment
CN110317782B (zh) * 2019-07-18 2023-06-13 天津瑞博斯生物技术有限公司 提高间充质干细胞复苏后存活的方法和所用的冻存液
CN112779209B (zh) * 2019-11-08 2023-01-24 合肥中科普瑞昇生物医药科技有限公司 原代乳腺上皮细胞培养基、培养方法及其应用
CN110923194B (zh) * 2019-12-23 2021-08-13 广东依浦赛生物科技有限公司 一种原代细胞培养的方法
TWI888659B (zh) * 2021-10-13 2025-07-01 芯芮生技開發股份有限公司 幹細胞條件培養基於製備抑制癌症組成物的用途
CN116889226A (zh) * 2022-04-02 2023-10-17 杭州启函生物科技有限公司 Nk细胞冻存液
IL317136A (en) * 2022-06-03 2025-01-01 Bluerock Therapeutics Lp Cell delivery device and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057153A1 (en) * 1998-05-01 1999-11-11 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20080242920A1 (en) * 2000-10-06 2008-10-02 Michael Dancu Method of conditioning a hybrid synthetic tubular structure to yield a functional human hybrid coronary bypass graft
WO2010108028A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2014150602A1 (en) * 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6733746B2 (en) 1996-03-12 2004-05-11 Invitrogen Corporation Hematopoietic cell culture nutrient supplement
CN1127571C (zh) 1997-02-20 2003-11-12 Dsm公司 用化学上确定的培养基以工业规模发酵生产有价值的化合物
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
JP2000201672A (ja) * 1999-01-11 2000-07-25 Asahi Medical Co Ltd 有核細胞の凍結保存用組成物
CN1368959A (zh) 1999-08-13 2002-09-11 大正制药株式会社 前列腺素衍生物
EP1132086B1 (en) 2000-01-31 2006-05-31 Pfizer Products Inc. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
JP2003225084A (ja) * 2000-12-28 2003-08-12 Japan Science & Technology Corp 凍結細胞保存剤
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
JP2005512592A (ja) 2001-12-21 2005-05-12 マウント・シナイ・ホスピタル 細胞性組成物ならびに細胞性組成物の作製法および細胞性組成物の使用法
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CA2585367A1 (en) 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
BRPI0607883A2 (pt) * 2005-02-28 2009-12-22 Regenetech Inc método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular
AU2006252363A1 (en) * 2005-06-02 2006-12-07 Stemcyte, Inc. Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
RU2425876C2 (ru) * 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP2069479A1 (en) * 2006-09-18 2009-06-17 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
EP2679221B1 (en) 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP3172963B1 (en) * 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
US9107909B2 (en) 2008-11-06 2015-08-18 Indiana University Research & Technology Corp. Materials and methods to enhance hematopoietic stem cells engraftment procedures
MX2011012183A (es) * 2009-05-20 2012-03-06 Cardio3 Biosciences Sa Composicion farmaceutica para el tratamiento de enfermedades cardiacas.
EP2499242B1 (en) 2009-11-15 2019-05-01 Indiana University Research&technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostagandin e2 receptors
JP5773347B2 (ja) * 2009-11-27 2015-09-02 国立大学法人 千葉大学 血液細胞の凍結保存剤
CA2807944C (en) 2010-08-12 2020-02-18 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
TWI535377B (zh) * 2011-09-01 2016-06-01 Storage, culture and application of umbilical cord tissue and its derived cells
US9925221B2 (en) * 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057153A1 (en) * 1998-05-01 1999-11-11 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20080242920A1 (en) * 2000-10-06 2008-10-02 Michael Dancu Method of conditioning a hybrid synthetic tubular structure to yield a functional human hybrid coronary bypass graft
WO2010108028A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2014150602A1 (en) * 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARCHUNDIA A ET AL: "Direct cardiac injection of G-CSF mobilized bone-marrow stem-cells improves ventricular function in old myocardial infarction", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 78, no. 3, 5 December 2005 (2005-12-05), pages 279 - 283, XP027713626, ISSN: 0024-3205, [retrieved on 20051205] *
M. MAIRHOFER ET AL: "Evaluation of a Xeno-Free Protocol for Long-Term Cryopreservation of Cord Blood Cells", CELL TRANSPLANTATION, vol. 22, no. 6, 3 October 2012 (2012-10-03), US, pages 1087 - 1099, XP055323027, ISSN: 0963-6897, DOI: 10.3727/096368912X657396 *
MARC CLOUTIER ET AL: "An alternative to dextran for the thawing of cord blood units", TRANSFUSION., vol. 56, no. 7, 3 July 2016 (2016-07-03), US, pages 1786 - 1791, XP055323274, ISSN: 0041-1132, DOI: 10.1111/trf.13633 *
P. RUBINSTEIN ET AL: "Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 92, no. 22, 24 October 1995 (1995-10-24), US, pages 10119 - 10122, XP055323127, ISSN: 0027-8424, DOI: 10.1073/pnas.92.22.10119 *
PESSINA A ET AL: "Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs", TOXICOLOGY IN VITRO, ELSEVIER SCIENCE, GB, vol. 23, no. 1, 1 February 2009 (2009-02-01), pages 194 - 200, XP025870257, ISSN: 0887-2333, [retrieved on 20081203], DOI: 10.1016/J.TIV.2008.11.006 *
See also references of WO2014152603A1 *
YUJI HIRATA ET AL: "Use of cryoprotectant-depleted allogeneic peripheral blood stem cells for transplantation", HEMATOLOGY, vol. 16, no. 4, 12 July 2011 (2011-07-12), LX, pages 221 - 224, XP055323064, ISSN: 1024-5332, DOI: 10.1179/102453311X13025568941664 *
Z SHU ET AL: "Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion", BONE MARROW TRANSPLANTATION, vol. 49, no. 4, 30 September 2013 (2013-09-30), GB, pages 469 - 476, XP055266980, ISSN: 0268-3369, DOI: 10.1038/bmt.2013.152 *

Also Published As

Publication number Publication date
WO2014152603A1 (en) 2014-09-25
AU2014239290A1 (en) 2015-10-08
CN105358679A (zh) 2016-02-24
JP2016513472A (ja) 2016-05-16
US9943545B2 (en) 2018-04-17
AU2014239290B2 (en) 2018-10-25
US20150044176A1 (en) 2015-02-12
JP2020089373A (ja) 2020-06-11
US20180193381A1 (en) 2018-07-12
EP2970894A1 (en) 2016-01-20
CA2906641C (en) 2022-10-25
US11135244B2 (en) 2021-10-05
CA2906641A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
EP2970894A4 (en) Stem cell culture media and methods of enhancing cell survival
EP3060650A4 (en) Culturing pluripotent stem cells
EP3006553A4 (en) Culture vessel and culture method
IL237527A0 (en) Devices and methods for growing cells
EP2971014A4 (en) CELL CULTURE METHODS
EP2971040A4 (en) CELL CULTURE METHODS
EP2904103B8 (en) Method for preparing induced pluripotent stem cells and its applications
EP3083978A4 (en) Media for cell culture
AU2014227804B2 (en) Serum-free cell culture medium
IL242344B (en) Arrays of distinct cell culture microenvironments, methods of preparing such arrays and uses thereof
EP3059308A4 (en) Method of inducing kidney from pluripotent stem cells
EP3201318A4 (en) Induction medium and methods for stem cell culture and therapy
SG11201502497RA (en) Sebocyte cell culturing and methods of use
SG11201509767UA (en) Medium for culturing stem cells
EP3050961A4 (en) Method for improving efficiency of inducing pluripotent stem cell
IL243634A0 (en) Method and medium for in vitro growth of stem cells
IL249202A0 (en) Cell culture methods and media containing n-acetylcysteine
EP3181686A4 (en) Culture medium and method for enriching and maintaining cancer stem cells (cscs) using said medium
EP3060924A4 (en) Pif-transfected cells and methods of use
EP3088415A4 (en) Method for inducing differentiation of pluripotent stem cells into endodermal cells
EP3008174A4 (en) Method of efficiently establishing induced pluripotent stem cells
EP3075846A4 (en) Cell culture medium and culture method using same
ZA201307857B (en) Culture medium for human mesenclymal stem cells
SG11201406771PA (en) Stem cell preparations and methods of use
GB201314614D0 (en) Media and methods for culturing embryos and stem cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161206

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20161130BHEP

Ipc: C12N 5/0789 20100101ALI20161130BHEP

Ipc: C12N 5/071 20100101AFI20161130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221001